With the rising incidence of diabetes and the escalating use of SGLT2 inhibitors in its management, thoroughly investigating potential risks to lower limbs is essential for responsible and informed medical care (Khouri et al., 2018). This evidence concerns the gene SLC5A2 and diabetes mellitus.